PMID- 34142932
OWN - NLM
STAT- MEDLINE
DCOM- 20220303
LR  - 20220303
IS  - 1744-8328 (Electronic)
IS  - 1473-7140 (Linking)
VI  - 21
IP  - 9
DP  - 2021 Sep
TI  - Surufatinib for the treatment of advanced extrapancreatic neuroendocrine tumors.
PG  - 917-926
LID - 10.1080/14737140.2021.1944110 [doi]
AB  - Introduction: Surufatinib (also known as HMPL-012, sulfatinib) is a novel oral 
      tyrosine kinase inhibitor (TKI), which has the dual activity of anti-angiogenesis 
      and immune regulation. In December 2020, surufatinib was approved as a 
      monotherapy for unresectable locally advanced or metastatic, progressive 
      nonfunctioning, well differentiated (grade 1 or 2) extrapancreatic neuroendocrine 
      tumors (epNETs) in China.Areas covered: In this paper, the chemical properties, 
      mechanism of action, pharmacokinetics, clinical efficacy, safety, and 
      tolerability of surufatinib for treatment of advanced extrapancreatic NETs are 
      introduced in detail. We performed a systematic review of the literature in 
      PubMed and the following keywords were used: 'surufatinib,' 'sulfatinib' and 
      'HMPL-012.'Expert opinion: Surufatinib is a potent, selective, and small-molecule 
      TKI that targets vascular endothelial growth factor receptor (VEGFR), fibroblast 
      growth factor receptor 1 (FGFR1) and colony stimulating factor 1 receptor 
      (CSF1R). Surufatinib showed an acceptable safety profile and encouraging 
      antitumor activity in patients with advanced epNETs. The most frequently observed 
      adverse events (AEs) were hypertension and proteinuria. Surufatinib provides a 
      new treatment option for patients with advanced epNETs. More clinical trials of 
      surufatinib are ongoing to develop a combination of therapy strategies and new 
      indications for malignancies.
FAU - Lu, Xiuhua
AU  - Lu X
AUID- ORCID: 0000-0001-9181-3899
AD  - Department of Clinical Pharmacy, Linyi Central Hospital, Linyi, Shandong, China.
FAU - Yan, Shibin
AU  - Yan S
AUID- ORCID: 0000-0001-6799-2575
AD  - Department of Hematology, Linyi Central Hospital, Linyi, Shandong, China.
FAU - Koral, Kelly Ann
AU  - Koral KA
AUID- ORCID: 0000-0003-3979-391X
AD  - Department of Pathology, School of Medicine, University of Pittsburgh, 
      Pittsburgh, Pennsylvania, USA.
FAU - Chen, Zhongguang
AU  - Chen Z
AUID- ORCID: 0000-0002-7378-4753
AD  - Department of Clinical Pharmacy, Linyi Central Hospital, Linyi, Shandong, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20210629
PL  - England
TA  - Expert Rev Anticancer Ther
JT  - Expert review of anticancer therapy
JID - 101123358
RN  - 0 (Indoles)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Pyrimidines)
RN  - 0 (Sulfonamides)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - B2K5L1L8S9 (surufatinib)
SB  - IM
MH  - Humans
MH  - Indoles
MH  - *Neuroendocrine Tumors/drug therapy/pathology
MH  - Protein Kinase Inhibitors/adverse effects
MH  - Pyrimidines/therapeutic use
MH  - Sulfonamides
MH  - Vascular Endothelial Growth Factor A
OTO - NOTNLM
OT  - Extrapancreatic neuroendocrine tumors
OT  - HMPL-012
OT  - sulfatinib
OT  - surufatinib
OT  - targeted therapy
EDAT- 2021/06/19 06:00
MHDA- 2022/03/04 06:00
CRDT- 2021/06/18 12:16
PHST- 2021/06/19 06:00 [pubmed]
PHST- 2022/03/04 06:00 [medline]
PHST- 2021/06/18 12:16 [entrez]
AID - 10.1080/14737140.2021.1944110 [doi]
PST - ppublish
SO  - Expert Rev Anticancer Ther. 2021 Sep;21(9):917-926. doi: 
      10.1080/14737140.2021.1944110. Epub 2021 Jun 29.